By Adam Bonislawski

Alameda, Calif.-based biotech firm Singulex this week announced it has been granted a US patent related to a cardiovascular disease biomarker assay using its Erenna single-molecule immunoassay platform.

The patent follows on one the company received last year for the Erenna platform itself, and comes as it begins efforts to develop the assay as a clinical diagnostic that it hopes to submit for US Food and Drug Administration approval within the next two years.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

New Mexico is re-doing its proposed science education standards after criticism, the Associated Press reports.

Agbio executives say gene editing will speed up breeding efforts, according to the Wall Street Journal.

La Trobe University's Jenny Graves has won the $250,000 Prime Minister's Prize for Science, the Guardian reports.

In Cell this week: post-treatment changes to melanoma genome, multi-omics analysis of muscle-invasive bladder cancer, and more.